Old West Investment Management LLC Takes Position in The Chemours Company $CC

Old West Investment Management LLC bought a new stake in The Chemours Company (NYSE:CC) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 348,549 shares of the specialty chemicals company’s stock, valued at approximately $7,152,000. Old West Investment Management LLC owned 0.23% of Chemours as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Atlas Capital Advisors Inc. acquired a new position in Chemours during the fourth quarter worth approximately $26,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Chemours in the fourth quarter valued at approximately $28,000. Covestor Ltd boosted its holdings in shares of Chemours by 204.7% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after acquiring an additional 1,748 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in shares of Chemours during the fourth quarter worth approximately $31,000. Finally, Rothschild Investment LLC grew its position in shares of Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after acquiring an additional 1,255 shares during the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours is expanding its low-GWP Opteon refrigerant portfolio to address rising cooling demand from AI-driven data centers. The initiative could support growth in a higher-demand market while aligning with customers’ decarbonization goals. Zacks article on Chemours refrigerants for data centers
• Positive Sentiment: CEO Denise Dignam bought 3,378 shares for approximately $50,500, while insider Gerardo Familiar Calderon purchased 1,935 shares for roughly $30,000. The open-market purchases may suggest that insiders view the recent share-price weakness as an opportunity. SEC filing on CEO purchase SEC filing on insider purchase
• Neutral Sentiment: BMO Capital Markets cut its price target from $26 to $18 but maintained an “outperform” rating, leaving implied upside while signaling reduced expectations. The broader analyst consensus remains “hold,” with an average target near $20.10.
• Negative Sentiment: A securities-fraud investigation involving Chemours was announced, creating a potential legal and reputational overhang for shareholders. The announcement does not establish wrongdoing, but it may increase uncertainty around the company.
• Negative Sentiment: JPMorgan lowered its price target from $22 to $15 and kept a “neutral” rating, while Zacks Research downgraded the stock from “strong buy” to “strong sell.” These actions reinforce concerns following Chemours’ recent quarterly EPS and revenue misses. Benzinga report on JPMorgan target cut Zacks rating report

Insider Buying and Selling at Chemours

In other Chemours news, CFO Shane Hostetter bought 3,350 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This represents a 3.37% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of Chemours stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 8,663 shares of company stock valued at $130,601. 0.85% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CC. Royal Bank Of Canada decreased their price target on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. dropped their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $17.00 target price on shares of Chemours in a report on Thursday. Morgan Stanley set a $18.00 target price on shares of Chemours in a research note on Monday, August 10th. Finally, BMO Capital Markets decreased their target price on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.10.

Chemours Stock Down 0.3%

Shares of Chemours stock opened at $15.81 on Monday. The company has a market cap of $2.38 billion, a P/E ratio of -8.28 and a beta of 1.43. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The Chemours Company has a one year low of $10.44 and a one year high of $28.67. The firm has a fifty day moving average of $18.54 and a two-hundred day moving average of $20.03.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the firm earned ($2.54) EPS. The firm’s revenue was down 1.5% on a year-over-year basis. On average, analysts forecast that The Chemours Company will post 0.88 earnings per share for the current year.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be given a $0.0875 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s dividend payout ratio (DPR) is presently -18.32%.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.